Related Experiment Video

Updated: Feb 16, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

589

Audiometric assessment of pediatric patients with cystic fibrosis

Kathryn L Kreicher1, Michael J Bauschard2, Clarice S Clemmens2

  • 1Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, Charleston, SC, United States; Case Western Reserve University School of Medicine, Cleveland, OH, United States.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|January 1, 2018
PubMed

Insights

Hearing loss is common in pediatric cystic fibrosis (CF) patients, with chronic otitis media and Eustachian tube dysfunction as key risk factors. Diabetes diagnosis in CF patients correlates with hearing decline.

Area of Science:

  • Otolaryngology
  • Pediatrics
  • Genetics

Background:

  • Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
  • Hearing impairment is a potential complication in pediatric CF patients.
  • Understanding the prevalence and risk factors for hearing loss in CF is crucial.

Purpose of the Study:

  • To evaluate the incidence and types of hearing impairment in children with cystic fibrosis.
  • To identify factors associated with the development and progression of hearing loss in this population.

Main Methods:

  • Retrospective analysis of the AudGen database from Children's Hospital of Philadelphia.
  • Analysis of audiograms for hearing loss type, pure-tone average (PTA), laterality, and changes over time.
  • Review of medical charts to correlate hearing outcomes with clinical factors.

Main Results:

  • Out of 217 pediatric CF patients, 69 (31.8%) exhibited hearing loss on initial audiogram.
  • Positive predictors for hearing loss included chronic otitis media, Eustachian tube dysfunction, and otorrhea.
  • Patients with CF and diabetes showed a significant decline in hearing over time compared to those without diabetes.

Conclusions:

  • This study represents the largest comprehensive analysis of hearing loss in pediatric CF patients.
  • Severe sinus disease may be associated with a lower risk of inflammatory middle ear disease and subsequent hearing loss.
  • Frequent monitoring and limiting ototoxic drug use are recommended for CF patients, especially those with complications like diabetes.
Abstract

Keywords:
AudiogramConductive hearing lossCystic fibrosisHearing lossOtitis mediaSensorineural hearing loss

More Related Videos

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.1K
Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

3.6K

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
896
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
549
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
281
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
318